References
- Mork NJ, Kolbenstvedt A, Austad J, Efficacy and skeletal side effects of two years’ acitretin treatment. Acta Derm Venereol (1992) 72: 445–8.
- Ellis CN, Pennes DR, Hermann RC et al, Long-term radiographic follow-up after isotretinoin therapy. J Am Acad Dermatol (1988) 18: 1252–61.
- Van Dooren-Greebe RJ, Lemmens JA, De Boo T et al, Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol (1996) 134: 71–6.
- Katz HI, Waalen J, Leach EE, Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol (1999) 41: S7–12.
- Soriatane [package insert]. Nutley, NJ: Roche Labora- tories, 2001.
- Nakhoda K, Greene G, Diffuse idiopathic skeletal hyper- ostosis. http:///www.emedicine.com/radio/topic218.htm
- Weinfeld RM, Olson PN, Maki DD, Griffiths HJ, The prevalence of diffuse idiopathic skeletal hyperostosis (DISH) in two large American Midwest metropolitan hospital populations. Skeletal Radiol (1997) 26: 222–5.
- Kiss C, O’Neill TW, Mituszova M et al, The prevalence of diffuse idiopathic skeletal hyperostosis in a population- based study in Hungary. Scand J Rheumatol (2002) 31: 226–9.
- Vezyroglou G, Mitropoulos A, Antoniadis C, A metabolic syndrome in diffuse idiopathic skeletal hyperostosis. A controlled study. J Rheumatol (1996) 23: 672–6.
- Gollnick HP, Oral retinoids—efficacy and toxicity in psoriasis. Br J Dermatol (1996) 135: 6–17.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285: 2508–9.
- Grundy SM, Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid- lowering therapy. Circulation (2002) 106: 2526–9.
- Gordon DJ, Probstfeld JL, Garrison RJ et al, High-density lipoprotein cholesterol and cardiovascular disease: four prospective American series. Circulation (1989) 79: 8–15.
- Avins AL, Neuhaus JM, Do triglycerides provide mean- ingful information about heart disease risk? Arch Intern Med (2000) 160: 1937–44.
- Hulley SB, Rosenman RH, Bawol RD et al, Epidemiology as a guide to clinical decision: the associations between triglyceride and coronary heart disease. N Engl J Med (1980) 302: 1383–9.
- Royer B, Ziegler F, Muret P et al, Acitretin-associated thrombotic stroke. Ann Pharmacother (2002) 36: 1879–82.
- Sacco RL, Benjamin EJ, Broderick JP et al, American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Risk factors. Stroke (1997) 28: 1507–17.
- Vahlquist C, Olsson AG, Lindholm A, Vahlquist A, Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study. Acta Derm Venereol (1995) 75: 377–80.
- Scandanavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344: 1383–9.
- Roenigk HH, Callen JP, Guzzo CA et al, Effects of acitretin on the liver. J Am Acad Dermatol (1999) 41: 584–8.
- McNamara IR, Muir J, Galbraith AJ, Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant (2002) 21: 1201–5.